Lupus-Like Anticoagulants, Modulation of the Protein C Pathway and Thrombosis

Jean-Marie Freyssinet; Jean-Pierre Cazenave

doi:10.1055/s-0038-1645954

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1987; 58(02): 679-681
DOI: 10.1055/s-0038-1645954

Review Article

Schattauer GmbH Stuttgart

Lupus-Like Anticoagulants, Modulation of the Protein C Pathway and Thrombosis

Jean-Marie Freyssinet

INSERM U.311, Bioiogie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France

,

Jean-Pierre Cazenave

INSERM U.311, Bioiogie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France

› Author Affiliations

Abstract

PDF Download

Key words

Lupus-like anticoagulants - Thrombosis - Phospholipids - Protein C pathway - Thrombogenic endothelium

PDF (284 kb)

References

References
1 Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemostasis Thromb 1982; 6: 263-285
2 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostasis Thromb 1972; 1: 75-95
3 Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622
4 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
5 Cohen AJ, Philipps TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-180
6 Gastineau DA, Kazmier FJ, Nichols WL, Bowie E JW. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Amer J Hematol 1985; 19: 265-275
7 Lechner K, Pabinger-Fashing I. Lupus anticoagulants and thrombosis. Haemostasis 1985; 15: 254-262
8 Hougie C. Circulating anticoagulants. In: Recent Advances in Blood Coagulation. Poller L. (Ed) Churchill Livingstone. Edinburgh: 1985 4. 63-90
9 Vermylen J, Blockmans D, Spitz B, Deckmyn H. Thrombosis and immune disorders. Clin Haematol 1986; 15: 393-412
10 Elias M, Eldor A. Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Ann Intern Med 1984; 144: 510-515
11 Zwaal R FA, Hemker HC. Blood cell membranes and haemostasis. Haemostasis 1982; 11: 12-39
12 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin MX, coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
13 Howard MA, Firkin BG. Investigations of the lupus-like inhibitor by-passing activity of platelets. Thromb Haemostas 1983; 50: 775-779
14 Dahlback B, Nilsson IM, Frohm B. Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 1983; 62: 218-225
15 Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time. The central role of phosphatidylserine. Thromb Haemostas 1984; 52: 172-175
16 Triplett DA, Brandt JT, Mass RL. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109: 946-951
17 Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CP S, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chern 1986; 261: 9672-9677
18 Alving CR. Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids 1986; 40: 303-314
19 Harris EN, Gharavi EA, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes G VR. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; II: 1211-1214
20 Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152-156
21 Hamsten A, Norberg R, Bjorkholm M, De Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986; I: 113-116
22 Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. In: Molecular Biology of the Cell. Garland Publishing; New York: 1983
23 Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41: 8-15
24 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: Detection of immunoglobulin interfering with prostacyclin production. Lancet 1981; 1: 244-246
25 Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979; 94: 312-323
26 Esmon CT. Regulation of protein C activation by components of the endothelial cell surface. In: Vascular endothelium in hemostasis and thrombosis. Gimbrone MA. (Ed). Churchill Livingstone; Edinburgh: 1986. p 99-119
27 Stenflo J. Structure and function of protein C. Semin Thromb Hemostasis 1984; 10: 109-121
28 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor V_a inactivation. J Biol Chem 1981; 256: 11128-11131
29 Griffin JH. Clinical studies of protein C. Semin Thromb Hemostasis 1984; 10: 162-166
30 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
31 Comp PC, DeBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62 5 Suppl 1 299a (Abstr)
32 Cariou R, Tobelem G, Caen J. L’anticoagulant circulant de type lupus, facteur de risque thrombotique par inhibition de 1’activation de la proteine C. C R Acad Sci Ser III-Vie 1986; 303: 113-118
33 Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J 1986; 238: 151-157
34 Galvin JB, Kurosawa S, Moore K, Esmon CT, Esmon NL. Reconstitution of rabbit thrombomodulin into phospholipid vesicles. J Biol Chem 1987; 262: 2199-2205
35 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemostas 1986; 55: 309-313
36 Friedman KD, Marlar RA, Gill JC, Endres-Brooks J, Montgomery RR. Protein S deficiency in patients with the lupus anticoagulant. Blood 1986; 68 5 Suppl 1 333 (Abstr)
37 Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 cancer cells. J Biol Chem 198 260: 15432-15438
38 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases anti-activator activity. Proc Natl Acad Sci USA; 1985; 82: 1121-1125
39 Van Hinsberg V WM, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
40 Cazenave JP, Klein-Soyer C, Beretz A. The vascular endothelium. An important site of blood-tissue exchanges. Inter Angiol 1984; 3: 27-32
41 Nawroth PP, Stern DM. Endothelial cells as active participants in procoagulant reactions. In: Vascular endothelium in hemostasis and thrombosis. Gimbrone MA. (Ed) Churchill Livingstone; Edinburgh: 1986. p 14-39
42 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-130
43 Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363-1375
44 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464
45 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
46 Nawroth PP, Cornelson S, Stern DM. Tumor necrosis factor upregulates factor IX/IXa binding sites and factor IXa-VIII-mediated factor Xa formation on endothelium. Circulation 1986; 74: 11-233 (Abstr)
47 Nawroth PP, Handley DA, Stern DM. Tumor necrosis factor-induced tumor killing involves coagulation. Circulation 1986; 11-233 (Abstr)